Form 4: MindMed Chief Legal Officer Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 11,491 common shares on June 25, 2025, to satisfy tax withholding obligations related to vested restricted stock units.

Summary

• Mark Sullivan, the Chief Legal Officer of Mind Medicine (MindMed) Inc. (MNMD), reported a transaction involving the company's common shares.
• On June 25, 2025, Mr. Sullivan sold 11,491 common shares.
• The shares were sold at a weighted average price of $6.8 per share, with individual transaction prices ranging from $6.67 to $7.03.
• This sale was conducted to satisfy withholding tax obligations associated with the settlement of vested restricted stock units.
• The transaction was executed pursuant to a Rule 10b5-1 plan, which was adopted on March 14, 2024.
• Following this transaction, Mr. Sullivan directly beneficially owns 305,130 common shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale of shares by an insider, it's explicitly for tax purposes under a pre-arranged plan (Rule 10b5-1), which is a common and non-discretionary event, not indicative of a lack of confidence in the company.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a non-discretionary sale and reducing concerns about insider sentiment.
• The sale was specifically for satisfying tax withholding obligations, which is a common and expected event for executives receiving equity compensation.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, although it is for tax purposes rather than a discretionary sale.

Risks

• No specific risks are detailed in this Form 4 filing beyond the routine nature of an insider transaction for tax purposes.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024.
• The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes and does not provide broader insights into industry trends or competitive landscape. It is specific to Mind Medicine (MindMed) Inc. and its executive compensation practices.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the total shares held by a key executive, but given it's for tax purposes, it's unlikely to be interpreted as a negative signal regarding the company's future prospects.
• Employees: The transaction relates to equity compensation, which is a common component of executive and employee remuneration, indicating the company's ongoing use of such incentives.

Next Steps

• The Reporting Person has undertaken to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Keywords

Mind Medicine, MNMD, Mark Sullivan, Chief Legal Officer, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Rule 10b5-1 Plan, Tax Obligations, Equity Compensation